¼¼°èÀÇ DNase, ¸®°¡Á¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - DNase ¿ëµµº°, ¸®°¡Á¦ ¿ëµµº°, RNA Æú¸®¸Þ¶óÁ¦ ¿ëµµº°, Áö¿ªº° Àü¸Á ¹× ¿¹Ãø(2024-2031³â)
Global DNases, Ligases, and RNA Polymerases Market Size, Share & Trends Analysis Report By DNases Application, By Ligases Application (Oligonucleotide Synthesis and Others), By RNA Polymerases Application, By Regional Outlook and Forecast, 2024 - 2031
»óǰÄÚµå : 1498455
¸®¼­Ä¡»ç : KBV Research
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 215 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,600 £Ü 5,072,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,320 £Ü 6,086,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,048 £Ü 8,521,000
PDF (Corporate User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È 10.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ½ÃÀå ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2031³â±îÁö 16¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

KBV Cardinal Matrix¿¡ Á¦½ÃµÈ ºÐ¼®À» ¹ÙÅÁÀ¸·Î, Thermofisher ScientificÀº DNase, ¸®°¡Á¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀåÀÇ ¼±±¸ÀÚÀÔ´Ï´Ù. 2022³â 2¿ù Thermofisher ScientificÀº ¸Þ½ÅÀú RNA¸¦ °³¹ßÇÏ´Â »ý¸í °øÇРȸ»çÀÎ ¸ð´Ù³ª¿Í Á¦ÈÞÇß½À´Ï´Ù. ÀÌ Çù¾÷ÇÏ¿¡ µÎ ȸ»ç´Â ¸ð´Ù³ªÀÇ COVID-19 ¹é½ÅÀÎ Spikevax¿Í ´Ù¸¥ ¿¬±¸ÁßÀÎ mRNA ¾à¹°À» ¹Ì±¹¿¡¼­ ä³Î¿¡¼­ È®½ÇÈ÷ ´ë±Ô¸ð·Î »ý»êÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çß½À´Ï´Ù. ¸ÓÅ© KGaA, ¾ÖÁú·±Æ® Å×Å©³î·ÎÁö½º, Ű¾Æ°Õ NV µîÀÇ ±â¾÷Àº Dnase, ¸®°¡Á¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀåÀÇ ÁÖ¿ä Çõ½ÅÀÚÀÇ ÀϺÎÀÔ´Ï´Ù.

COVID-19ÀÇ ¿µÇ⠺м®

ÆÒµ¥¹Í Ãʱ⠴ܰ迡¼­´Â ¼¼°è °ø±Þ¸Á, ¹°·ù, Á¦Á¶ ¾÷¹«ÀÇ È¥¶õÀ¸·Î ÀÎÇØ DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ¹× ±âŸ ºÐÀÚ »ý¹°ÇÐ ½Ã¾àÀÇ °¡¿ë¼º¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±¹°æ Æó¼â, ¿©Çà Á¦ÇÑ, ºÀ¼â Á¶Ä¡·Î »óǰ À̵¿ÀÌ ¹æÇصǾúÀ¸¸ç Á¦Ç° ÃâÇÏ ¹× ¹è¼ÛÀÌ Áö¿¬µÇ¾ú½À´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀº Çмú±â°ü, »ý¸í°øÇбâ¾÷, Á¦¾àȸ»çÀÇ ¿¬±¸°³¹ß Ȱµ¿À» È¥¶õ½ÃÄÑ ½ÇÇèÀÇ Å¸ÀÓ¶óÀΰú ÇÁ·ÎÁ§Æ® ÁøÇà¿¡ ¿µÇâÀ» ÁÖ¾ú½À´Ï´Ù. µû¶ó¼­ COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâÀº ½ÃÀå¿¡ Áß°£ Á¤µµÀÇ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¿äÀÎ

°Ô³ð Á¶»ç´Â DNA¿Í RNA ¼­¿­¿¡ ´ëÇÑ ¿¬±¸¸¦ Æ÷ÇÔÇϸç, À¯ÀüÀû º¯ÀÌ, À¯ÀüÀÚ ¹ßÇö ÆÐÅÏ ¹× »ý¹°ÇÐÀû °úÁ¤ÀÇ ±Ùº»ÀûÀÎ ºÐÀÚ ¸ÞÄ¿´ÏÁòÀ» ÀÌÇØÇÕ´Ï´Ù. DNase, ¸®°¡Á¦, RNA Æú¸®¸Þ¶óÁ¦´Â ½ÃÄö½Ì, PCR ÁõÆø, Ŭ·Î´× ¹× À¯ÀüÀÚ ¹ßÇö ºÐ¼®°ú °°Àº ÇÙ»ê Á¶ÀÛ ±â¼ú¿¡ »ç¿ëµÇ´Â Áß¿äÇÑ È¿¼Ò·Î ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. µû¶ó¼­ °Ô³ð Á¶»çÀÇ È®´ë´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

»ý¸í°øÇÐ ¹× Á¦¾à »ê¾÷Àº ¹ÙÀÌ¿À ÀǾàǰ °³¹ßÀÇ ´Ù¾çÇÑ ¿ëµµ·Î DNase, ¸®°¡Á¦, RNA Æú¸®¸Þ¶óÁ¦¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. À̵é È¿¼Ò´Â ºÐÀÚ Å¬·Î´×, À¯ÀüÀÚ ¹ßÇö, ´Ü¹éÁú »ý»ê ¹× Ä¡·á ´Ü¹éÁú, ´ÜÀÏŬ·Ð Ç×ü, À¯ÀüÀÚ Ä¡·á¿Í °°Àº »ý¹°ÇÐÀû Á¦Á¦ »ý»ê¿¡ »ç¿ëµÇ´Â ÀçÁ¶ÇÕ DNA ±â¼ú¿¡ ÇʼöÀûÀÔ´Ï´Ù. µû¶ó¼­ »ý¸í°øÇÐ ¹× Á¦¾à¾÷°è´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ

È¿¼Ò »ý»ê¿¡´Â ¹ßÈ¿, Á¤Á¦, ¹èÇÕ°ú °°Àº º¹ÀâÇÑ Á¦Á¶ °øÁ¤ÀÌ ¼ö¹ÝµÇ¸ç Ư¼ö Àåºñ, Àåºñ ¹× Àü¹® Áö½ÄÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÇÁ·Î¼¼½º´Â ÀÚ¿ø Áý¾àÀûÀ̸ç, ÀÎÇÁ¶ó, ±â¼ú, ¼÷·ÃµÈ Àη¿¡ ´ëÇÑ ¾öû³­ ÅõÀÚ°¡ ÇÊ¿äÇÏ¸ç »ý»ê ºñ¿ëÀÌ ³ô½À´Ï´Ù. µû¶ó¼­, È¿¼Ò »ý»ê ºñ¿ëÀÇ ³ôÀÌ´Â ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

DNasesÀÇ ¿ëµµº° Àü¸Á

DNasesÀÇ ¿ëµµ¿¡ µû¶ó ½ÃÀåÀº ¹ÙÀÌ¿À ÀǾàǰ ó¸®¿Í ±âŸ·Î ³ª´¹´Ï´Ù. ±âŸ ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 23%ÀÇ ¼öÀÍ Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù. DNases´Â Åä¾ç ¹× ¼öÁß DNA ¿À¿° ¹°ÁúÀ» ºÐÇØÇϱâ À§ÇØ È¯°æ »ý¸í °øÇп¡¼­ »ç¿ëµÇ¸ç ¿À¿° µÈ ȯ°æÀÇ »ýü Á¶Á¤¿¡ µµ¿òÀÌ µË´Ï´Ù. DNases´Â À¯Á¦Ç° ¹× °í±â¿Í °°Àº ½Äǰ¿¡¼­ DNA¸¦ Á¦°ÅÇÏ°í ºÎÆÐ¸¦ ¹æÁöÇÏ°í º¸Á¸ ±â°£À» ¿¬ÀåÇϱâ À§ÇØ ½Äǰ »ê¾÷¿¡¼­µµ »ç¿ëµË´Ï´Ù.

¸®°¡Á¦ÀÇ ¿ëµµº° Àü¸Á

¸®°¡Á¦ÀÇ ¿ëµµ¿¡ µû¶ó, ½ÃÀåÀº ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ¹× ±âŸ·Î ºÐ·ùµË´Ï´Ù. 2023³â¿¡´Â ´Ù¸¥ ºÎ¹®ÀÌ ½ÃÀå¿¡¼­ 56%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ¸®°¡Á¦´Â ºÐÀÚ Å¬·Î´× ¹× ¼­ºêŬ·Î´× ÀýÂ÷ µ¿¾È º¤ÅÍ¿Í °°Àº DNA ´ÜÆíÀ» °áÇÕÇϰí DNA¸¦ »ðÀÔÇÕ´Ï´Ù. ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ´ÜÆíÀ» ´õ ±ä DNA ¼­¿­¿¡ ¿¬°áÇÔÀ¸·Î½á ÇÕ¼º À¯ÀüÀÚÀÇ Á¶¸³À» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.

RNA Æú¸®¸Þ¶óÁ¦ÀÇ ¿ëµµº° Àü¸Á

RNA Æú¸®¸Þ¶óÁ¦ÀÇ ¿ëµµº°·Î, ½ÃÀåÀº mRNA »ý»ê°ú ±× ¹Û¿¡ ³ª´µ¾îÁ® ÀÖ½À´Ï´Ù. ±âŸ ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ ÇöÀúÇÑ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. RNA Æú¸®¸Þ¶óÁ¦´Â IVT ¹ÝÀÀ¿¡ »ç¿ëµÇ¸ç in vitro¿¡¼­ DNA ÁÖÇüÀ¸·ÎºÎÅÍ RNA Àü»ç »ê¹°À» »ý¼ºÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÇÕ¼º RNA ºÐÀÚ´Â ºÐÀÚ »ý¹°ÇÐ Á¶»ç¿¡¼­ ±ÍÁßÇÑ µµ±¸·Î ÀÛ¿ëÇÏ¿© ´Ù¾çÇÑ ¿ëµµÀÇ RNA ÇÁ·Îºê, Ç¥ÁØ, ´ëÁ¶±º ¹× ¹ßÇö º¤Å͸¦ »ý¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù.

Áö¿ªº° Àü¸Á

Áö¿ªº°·Î º¸¸é ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿, ¾ÆÇÁ¸®Ä«¿¡ °ÉÃÄ ºÐ¼®µÇ°í ÀÖ½À´Ï´Ù. 2023³â¿¡´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ½ÃÀå¿¡¼­ 28%ÀÇ Å« ¼öÀÍ Á¡À¯À²À» âÃâÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº À¯ÀüÀû µ¹¿¬º¯ÀÌ, Áúº´ ¸ÞÄ¿´ÏÁò ¹× Áý´Ü À¯ÀüÇÐÀ» ÀÌÇØÇÏ´Â ´ë±Ô¸ð °Ô³ð Á¶»ç ÀÌ´Ï¼ÅÆ¼ºêÀÇ º»°ÅÁöÀÔ´Ï´Ù. DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦´Â DNA ½ÃÄö½Ì, À¯ÀüÀÚ ¹ßÇö ºÐ¼®, À¯ÀüÀÚ ÆíÁý µîÀÇ °Ô³ð Á¶»ç¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, Áö¿ª ÀüüÀÇ Çмú±â°ü ¹× Á¶»ç±â°ü¿¡¼­ È¿¼ÒÁ¦Ç° ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

Á¦2Àå ½ÃÀå ¿ä¶÷

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå °æÀï ºÐ¼®-¼¼°è

Á¦5Àå ¼¼°è ½ÃÀå : DNases ¿ëµµº°

Á¦6Àå ¼¼°è ½ÃÀå : ¸®°¡Á¦ÀÇ ¿ëµµº°

Á¦7Àå ¼¼°è ½ÃÀå : RNA Æú¸®¸Þ¶óÁ¦ÀÇ ¿ëµµº°

Á¦8Àå ¼¼°è ½ÃÀå : Áö¿ªº°

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦10Àå DNase, ¸®°¡Á¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀåÀÇ ¼º°ø Çʼö Á¶°Ç

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global DNases, Ligases, And RNA Polymerases Market size is expected to reach $1.6 billion by 2031, rising at a market growth of 10.4% CAGR during the forecast period.

North America is home to some of the world's leading biotechnology and pharmaceutical companies, particularly the United States. Thus, the North America region acquired $273.68 million revenue in 2023. Increased use of DNases, Ligases, And RNA Polymerases results from this financial support. These enzymes are necessary for various molecular biology and genetic engineering applications. Specific grants and subsidies targeted at innovative pharmaceutical research bolster the demand for these enzymes as they are critical tools in developing new drugs and therapies.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In 2022, February, QIAGEN formed a partnership with Singular Genomics Systems to verify its QIAseq kits, a product line for both RNA and DNA sample prep, with the G4 analysis platform. Additionally, In 2021, August, QIAGEN came into a partnership with GT Molecular to deliver a comprehensive wastewater workflow solution developed to allow management of COVID-19 outbreaks by U.S. and Canadian laboratories, with forthcoming opportunities to deliver the solution in other countries.

Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the DNases, Ligases, And RNA Polymerases Market. In February 2022, Thermo Fisher Scientific joined hands with Moderna, a biotechnology company developing messenger RNA. Under this collaboration, the companies aimed to allow reliable large-scale manufacturing in the U.S. of Spikevax, Moderna's COVID-19 vaccine, and other investigational mRNA drugs in its channel. Companies such as Merck KGaA, Agilent Technologies, Inc., Qiagen N.V are some of the key innovators in DNases, Ligases, And RNA Polymerases Market.

COVID-19 Impact Analysis

In the early stages of the pandemic, disruptions to global supply chains, logistics, and manufacturing operations affected the availability of DNases, Ligases, RNA Polymerases, and other molecular biology reagents. Border closures, travel restrictions, and lockdown measures impeded the movement of goods, leading to product shipment and distribution delays. The COVID-19 pandemic disrupted research and development activities in academic institutions, biotechnology companies, and pharmaceutical firms, affecting experimental timelines and project progress. Thus, the Impact of the COVID-19 pandemic had a moderate impact on the market.

Market Growth Factors

Genomic research involves the study of DNA and RNA sequences to understand genetic variations, gene expression patterns, and molecular mechanisms underlying biological processes. DNases, Ligases, And RNA Polymerases are essential enzymes used in nucleic acid manipulation techniques such as sequencing, PCR amplification, cloning, and gene expression analysis, driving market demand. Hence, the expansion of genomic research is driving the market's growth.

The biotechnology and pharmaceutical industries rely heavily on DNases, Ligases, And RNA Polymerases for various applications in biopharmaceutical development. These enzymes are essential for molecular cloning, gene expression, protein production, and recombinant DNA technology used in biologics production, such as therapeutic proteins, monoclonal antibodies, and gene therapies. Thus, the biotechnology and pharmaceutical industries are propelling the market's growth.

Market Restraining Factors

Enzyme production involves complex manufacturing processes, including fermentation, purification, and formulation, which require specialized equipment, facilities, and expertise. These processes are resource-intensive and require substantial investments in infrastructure, technology, and skilled personnel, contributing to high production costs. Therefore, the high enzyme production costs are propelling the market's growth.

DNases Application Outlook

Based on DNases application, the market is divided into biopharmaceutical processing and others. The others segment witnessed a 23% revenue share in the market in 2023. DNases are utilized in environmental biotechnology to degrade DNA contaminants in soil and water, aiding in the bioremediation of polluted environments. DNases are also used in the food industry to remove DNA from food products, such as dairy and meat, to prevent spoilage and improve shelf life.

Ligases Application Outlook

On the basis of Ligases application, the market is segmented into oligonucleotide synthesis and other. In 2023, the other segments attained a 56% revenue share in the market. Ligases join DNA fragments, such as vectors, during molecular cloning and subcloning procedures and insert DNA. They facilitate the assembly of synthetic genes by ligating oligonucleotide fragments into longer DNA sequences.

RNA Polymerases Application Outlook

By RNA polymerases application, the market is divided into mRNA production and others. The others segment procured a remarkable revenue share in the market in 2023. RNA polymerases are utilized in IVT reactions to produce RNA transcripts from DNA templates in vitro. These synthetic RNA molecules serve as valuable tools in molecular biology research, enabling the generation of RNA probes, standards, controls, and expression vectors for various applications.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated a substantial 28% revenue share in the market. The Asia Pacific region is home to large-scale genomic research initiatives to understand genetic variations, disease mechanisms, and population genetics. DNases, Ligases, And RNA Polymerases play crucial roles in genomic research, including DNA sequencing, gene expression analysis, and genome editing, driving demand for enzyme products in academic and research institutions across the region.

Recent Strategies Deployed in the Market

List of Key Companies Profiled

Global DNases, Ligases, And RNA Polymerases Market Report Segmentation

By DNases Application

By Ligases Application

By RNA Polymerases Application

By Geography

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Competition Analysis - Global

Chapter 5. Global DNases, Ligases, And RNA Polymerases Market by DNases Application

Chapter 6. Global DNases, Ligases, And RNA Polymerases Market by Ligases Application

Chapter 7. Global DNases, Ligases, And RNA Polymerases Market by RNA Polymerases Application

Chapter 8. Global DNases, Ligases, And RNA Polymerases Market by Region

Chapter 9. Company Profiles

Chapter 10. Winning Imperatives of DNases, Ligases, And RNA Polymerases Market

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â